蔚藍生物(603739.SH):“土苓茅根顆粒”獲得新獸藥註冊證書
格隆匯 8 月 31日丨蔚藍生物(603739.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准公司與其他單位聯合申報的“土苓茅根顆粒”為三類新獸藥,並於近日核發了《新獸藥註冊證書》(農業農村部公告第327號)。
新獸藥名稱:土苓茅根顆粒;新獸藥註冊證書號:(2020)新獸藥證字37號;註冊分類:三類;主要成分:土茯苓、白茅根、槐花、益母草、廣藿香。作用與用途:清熱利濕,健脾化濁。用於濕熱及飼料蛋白質含量過高引起的腎腫濕熱證。用法與用量:混飲,每1L水,雞1g,每日2次,連用5天。
土苓茅根顆粒是由公司與青島動保國家工程技術研究中心有限公司、石家莊江山動物藥業有限公司、湖北迴盛生物科技有限公司、山東欣慧瑞生物科技有限公司、廣東海納川生物科技股份有限公司、山東省獸藥質量檢驗所、成都新精華藥業有限公司、石家莊市金元康牧藥業有限公司、青島信諾邦生物科技有限公司、江西邦誠動物藥業有限公司聯合開發的國家三類新獸藥。
該產品經實驗室藥學研究、臨牀試驗、新獸藥註冊等階段,農業農村部於近日已公告核發新獸藥註冊證書。該產品開發累計投入研發費用為380.40萬元。
新獸藥證書的取得是公司持續重視科技創新、加大研發投入的結果,進一步體現了公司的創新能力,也是公司積極推擠技術市場化的成果。土苓茅根顆粒的成功研製,解決了雞腎臟系統疾病防治難、用藥後反而加劇腎臟損傷、應激大等難題,降低了家禽養殖成本,同時為生產公司的業務帶來新的業績增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.